



Review article

T cell response to FVIII

Marc Jacquemin^{a,*}, Jean-Marie Saint-Remy^{a,b}^a University of Leuven, Center for Molecular and Vascular Biology, Herestraat 49 Bus 913, B3000 Leuven, Belgium^b ImCyse s.a.-n.v., Bioincubator II, Gaston Geenslaan 1, B-3001 Leuven, Belgium

ARTICLE INFO

Article history:

Received 18 August 2015

Revised 16 September 2015

Accepted 16 September 2015

Available online 26 September 2015

Keywords:

FVIII inhibitor

Hemophilia A

T cells

Immune tolerance induction

ABSTRACT

Several lines of evidence indicate that the immune response to Factor VIII (FVIII) in patients with hemophilia A is T cell-dependent. This review highlights the link between the epitope specificity of FVIII-specific T cells and their potential roles in different categories of patients. FVIII-specific T cells able to recognize wild-type (i.e. therapeutic) FVIII but not the mutated self FVIII of hemophilia patients have been identified in patients with mild/moderate hemophilia carrying some point mutations. Such T cells likely contribute to the higher frequency of neutralizing anti-FVIII antibodies (inhibitors) development in these patients. In contrast, as yet no T cells have been identified that can differentiate between FVIII molecules with non-hemophilia-causing single amino acid variants encoded by non-synonymous single-nucleotide polymorphisms in the F8 gene. Other mechanisms are therefore still to be identified that will explain the clinically noted differences in the incidence of inhibitor development between patients of different races who are known to have differences at these sites. Beside information about the mechanism of inhibitor development, the analysis of FVIII-specific T cells has provided tools to develop novel diagnostic and therapeutic approaches, such as the generation of FVIII-specific regulatory T cells that may be useful in preventing or suppressing the immune response to FVIII.

© 2015 Elsevier Inc. All rights reserved.

Contents

1. Introduction	8
2. FVIII-specific T cells in control subjects and in patients with hemophilia A and inhibitor	9
3. FVIII-specific T cells in patients with mild/moderate hemophilia A and inhibitor	9
4. FVIII polymorphisms and FVIII-specific T cells	10
5. FVIII-specific T cells and immune tolerance induction (ITI)	10
6. Perspectives	10
Acknowledgments	10
References	10

1. Introduction

Patients with severe hemophilia A (FVIII activity less than 1%) who are treated by the administration of recombinant or plasma-derived FVIII concentrates develop FVIII inhibitory antibodies in about 20–40% of cases [1]. Several lines of evidence indicate that the immune response to FVIII is T cell-dependent. First, the observation that a large proportion of anti-FVIII antibodies belong to the

IgG4 subclass [2] pinpoints a role for T cells in the development of the humoral response to FVIII since isotype switching is T cell-dependent. Second, hypermutations are consistently detected in the genes coding for the variable part of anti-FVIII antibodies obtained either by immortalization of peripheral blood lymphocytes of patients with inhibitor [3] or by phage display technology [4]. This indicates that B cells producing anti-FVIII antibodies undergo affinity maturation processes, which also require specific T cell help [5]. Lastly, in patients with an established humoral response to FVIII, HIV infection leads to the disappearance of FVIII inhibitor when T cell counts decline, demonstrating the requirement for T cells in this process [6]. The objective of this review is

* Corresponding author.

E-mail addresses: Marc.jacquemin@med.kuleuven.be (M. Jacquemin), Jean-Marie.Saint-Remy@med.kuleuven.be (J.-M. Saint-Remy).

to highlight the epitope specificity and the potential role of FVIII-specific T cells that have been identified in patients with hemophilia A and inhibitor.

2. FVIII-specific T cells in control subjects and in patients with hemophilia A and inhibitor

FVIII-specific T cells were first identified in the peripheral blood of hemophilia A patients with inhibitor using T cell proliferation assays with native FVIII [7]. The antigenic determinants (epitopes) recognized by such T cells were studied using synthetic peptides covering the entire FVIII molecule [8]. Epitopes were mapped in all domains of the FVIII molecule.

Surprisingly, T cells proliferating in response to FVIII peptides have also been identified in hemophilia A patients without inhibitor as well as in healthy individuals. In these reports only minor differences were identified between FVIII-specific T cells from healthy individuals and those from hemophilia A patients with or without inhibitor [8–11]. This lack of clear-cut difference at the T cell level has raised questions about the role of FVIII-specific T cells in the response to FVIII. It may be the case that FVIII-specific T cells are unnecessary for the development of an immune response to FVIII, although this seems unlikely given that in patients with an established humoral response to FVIII, HIV infection leads to the disappearance of FVIII inhibitor when T cell counts decline [6]. Alternatively, qualitative differences in the phenotype of FVIII-specific T cells, such as the profile of interleukin production, may sustain tolerance or the induction of an immune response to FVIII [12,13].

Interestingly, in addition to FVIII-specific T cells, antibodies to FVIII have also been isolated from control subjects and from hemophilia A patients without clinically-relevant inhibitor [14–16]. The paradoxical presence of anti-FVIII antibodies in subjects with normal FVIII levels has only recently been explained by the observation that the affinity of these antibodies is much lower than that of inhibitory antibodies [17].

3. FVIII-specific T cells in patients with mild/moderate hemophilia A and inhibitor

In contrast to patients with severe hemophilia A, the development of inhibitor is rare in mild/moderate hemophilia A patients (FVIII: 1–40%) [18]. Nevertheless, mild/moderate patients carrying certain mutations present an incidence of inhibitor formation comparable to that of patients with severe hemophilia A. Such mutations have been located in the amino-terminal part of the C2 domain of FVIII, the carboxy-terminal part of the C1 domain, and the amino-terminal region of the A2 domain [19].

Analysis of polyclonal and monoclonal anti-FVIII antibodies derived from patients with mild/moderate hemophilia A and inhibitor demonstrated that certain antibodies exclusively recognized epitope(s) present on wild-type FVIII but not on mutated counterparts carrying the Arg593Cys or Arg2150His substitutions [20–23]. The B lymphocytes of such patients were therefore able to make the distinction between self (mutated) and exogenous (normal) FVIII. These observations raised the question of whether FVIII-specific T cells from patients with mutated FVIII could also recognize epitopes on normal exogenous FVIII that were absent on the patients' own mutated FVIII. Two techniques were exploited to answer this question.

The first approach allowed the expansion and characterization of T cells present in the blood irrespective of their epitope specificity. Using this method, the T cell response to FVIII was studied in a mild hemophilia A patient carrying an Arg2150His substitution in the C1 domain who presented with a high-titer inhibitor toward

normal but not self-FVIII. T cell lines from this patient were expanded and cloned by stimulation with FVIII presented by autologous FVIII-specific B cell lines. These FVIII-specific T cells recognized a peptide encompassing residue Arg2150 of FVIII, the residue mutated in the patient's FVIII gene, and did not recognize recombinant FVIII carrying the substitution Arg2150His. This demonstrated that the C1 domain of wild-type FVIII contains T cell epitopes that are absent in FVIII carrying the mutation Arg2150His [24]. This mutation likely alters the ability of T cells to recognize the mutated FVIII peptide associated with MHC molecules, since immunopurified MHC class II molecules were found to bind to the mutated peptide nearly as effectively as the native peptide.

In a separate approach, FVIII-specific T cells from patients with mutated FVIII were amplified using peptides derived from normal FVIII that corresponded to the region where the mutation was located in the patients' own FVIII gene. This technique can also be used in tetramer guided epitope mapping, where the specific T cells involved can be identified after labeling with a tetramer of MHC class II molecules loaded with the relevant peptide. However, although this technique has proven very efficient at identifying T cells of a predefined specificity, it cannot provide information about T cells that recognize epitopes in other regions. Using this approach, the T cell response of a subject with mild hemophilia A with the missense genotype was characterized for 1 year following his initial inhibitor response [25]. His T cells were stimulated and expanded with pools of peptides covering the C2 domain.

With this method, a T cell epitope sequence containing the 2201 residue was identified. Interestingly, peptides containing the native FVIII Ala2201 were recognized by the patient's CD4 T cells collected up to 1 year after inhibitor development, whereas the mutated Pro2201 peptide was recognized only around the time of the initial peak response. These results were confirmed by the isolation of T cell clones that both proliferated in response to peptides containing Ala2201 and recognized the Ala2201 peptide bound to MHC-class II tetramers. Unexpectedly, no T cell clones recognized the hemophilic (Pro2201) peptides. These results suggest that the epitope specificity of the FVIII-specific T cells evolved over time in this patient, leading to a loss of recognition of the self-epitope. However, the relevance of T cell recognition of the self-peptide *in vivo* remains unclear because binding of the mutated peptide to the patient's MHC class II molecules was about 20-fold weaker than the binding of the wild-type peptide [25].

T cell clones recognizing FVIII peptides involving residue 2201 have also been derived by tetramer guided epitope mapping from another patient with the FVIII-Ala2201Pro genotype and a non-clinically-significant inhibitor response. Several clones recognized peptides containing the Ala2201 residue. In contrast to the above case, these clones were also activated by peptides containing Pro2201 [26], however the concentration of mutated peptide required to activate the T cells was between 30- and more than 100-fold higher than that of the native peptide, again raising the question of whether such T cells can actually be activated by the autologous mutated FVIII molecule *in vivo* [26].

FVIII-specific T cell clones recognizing peptides involving another hemophilic missense site, Arg593Cys, have also been identified in two unrelated subjects with mild hemophilia A [27]. Unexpectedly, peptides containing both the wild-type Arg593 residue and the hemophilic Cys593 residue elicited similar levels of proliferation of the T cell clones. These observations do not fit with the concept that presentation of wild-type FVIII epitopes rather than the mutated patient FVIII increases inhibitor risk by activating T cells that do not recognize self-FVIII. However, in tetramer guided epitope mapping, CD4+ T cells from patients were stained by tetramers loaded with wild-type and not mutated peptides, suggesting a lower-avidity interaction of T cells with the tetramers and thus possibly with antigen-presenting cells [27].

Collectively, these observations demonstrate that the mutated FVIII that is present in some patients with mild/moderate hemophilia A can be distinguished from normal FVIII by the immune system not only at the B cell level but also at the T cell level, and may predispose patients to inhibitor formation.

4. FVIII polymorphisms and FVIII-specific T cells

Three non-synonymous single-nucleotide polymorphisms (ns-SNP) encoding amino acid sequence variations that do not cause hemophilia have been detected with an increased incidence in African American hemophilia A patients compared to Caucasian patients; these effects were associated with an increased incidence of inhibitor in patients treated with FVIII concentrates [28]. Since the recombinant FVIII products that are currently available only express one or none of these ns-SNPs and since plasma-derived FVIII concentrates are purified from multiple donors, it has been hypothesized that the immune system may recognize the differences between ns-SNPs present on self-FVIII versus exogenous FVIII by mechanisms similar to those reported in patients with mild/moderate hemophilia A [28]. Such a phenomenon could explain the increased inhibitor incidence that has been reported in African American hemophilia A patients [29,30]. Unexpectedly, the association between these non-hemophilic ns-SNPs and inhibitor development has also been observed in patients with severe hemophilia A who carry an inversion of intron 22 in their FVIII gene [28]. However, this finding appeared counterintuitive because patients with an inversion of intron 22 would not be expected to produce FVIII protein due to the nature of this alteration. A potential explanation to this paradox is provided by the observation that individuals with the intron 22 inversion have normal levels of FVIII mRNA and intracellular FVIII protein in some cell types, such as B lymphoblastoid cells and liver cells [31]. This FVIII production may be sufficient to allow central or peripheral tolerance to self-FVIII in patients with an inversion of intron 22, thereby allowing the immune system to recognize the difference between self-FVIII and FVIII concentrates with ns-SNP(s) different to those of the self-FVIII.

In contrast to these observations, other recent studies have not found any statistical association between F8 polymorphisms and inhibitor incidence [32–34]. One such study sought to determine whether African American patients with hemophilia A and inhibitor have FVIII-specific T cells that are able to distinguish between normal FVIII concentrates and FVIII peptides carrying alternative ns-SNPs [34]. In this study, CD4⁺ T cells from subjects who had been treated with FVIII products carrying other ns-SNPs than those potentially expressed by the patients were analyzed using peptide-loaded MHC class II tetramers in an attempt to identify T cell responses to sequences encoded by the different ns-SNPs. None of the experiments using tetramers loaded with FVIII peptides containing alternative ns-SNPs produced unambiguous, tetramer-high staining. This indicates that the FVIII products currently available do not provoke T cell responses as a result of exposure to potential neo-epitopes encoded by ns-SNPs in an appreciable fraction of African American hemophilia A patients. Thus, these experiments do not support the paradigm that T cell responses to FVIII regions encoded by non-hemophilic ns-SNPs may contribute to the higher incidence of inhibitor reported in African American patients with hemophilia A [34]. In future studies it will be interesting to determine the epitopes recognized by FVIII-specific T cells in African American patients using techniques that do not require any preliminary assumptions about the epitopes that are recognized by these patients' T cells.

5. FVIII-specific T cells and immune tolerance induction (ITI)

The prolonged administration of FVIII frequently results in the disappearance of inhibitor antibodies (immune tolerance induction, ITI) [35]. However, although ITI has been used for suppressing inhibitor production for more than 30 years, only limited information is available regarding its mode of action. In animal models the administration of high doses of an antigen commonly results in the elimination of the associated antigen-specific T cells, a phenomenon called deletion [36,37]. To determine whether such a mechanism restores tolerance to FVIII following ITI, FVIII-specific T cells from successfully desensitized patients were studied. FVIII-specific T oligoclonal cell lines were expanded from the blood of one of five successfully desensitized patients following repeated stimulation with autologous dendritic cells loaded with FVIII [38]. These observations demonstrated that successful ITI can occur in these patients without the deletion of FVIII-specific T cells.

6. Perspectives

The treatment of patients with inhibitor will benefit from further studies on FVIII-specific T cells in more than one perspective. The analysis of such T cells during ITI will undoubtedly help to understand the mechanism of action of this treatment and allow us to identify biomarkers of success or failure, as well as providing a rationale for optimizing ITI protocols. In addition, the characterization of FVIII-specific T cells could also allow the development of patient-specific novel therapies to prevent or suppress inhibitor development. Recently, regulatory T cells were transfected with genes encoding FVIII-specific T cell receptors. This allowed the generation of FVIII-specific regulatory T cells that may be useful in preventing or suppressing the immune response to FVIII, as has been recently demonstrated in animal experiments [39]. In the future, this strategy could be exploited to regulate the immune response to FVIII by autologous FVIII-specific regulatory T cells.

Acknowledgments

This work was supported by the KU Leuven Pfizer and Baxter Chairs for Hemophilia to M.J., and the Programma Financiering KU Leuven (PF/10/014). J.-M.S.R. is employee and shareholder of ImCyse s.a.-n.v.

References

- [1] L.W. Hoyer, D. Scandella, Factor VIII inhibitors: structure and function in autoantibody and FVIII inhibitors, *Semin. Hematol.* 31 (1994) 1–5.
- [2] B.R. Andersen, W.D. Terry, Gamma G4-globulin antibody causing inhibition of clotting factor VIII, *Nature* 217 (1968) 174–175.
- [3] M.G. Jacquemin, B.G. Desqueper, A. Benhida, L. Vander Elst, M.F. Hoylaerts, M. Bakkus, K. Thielemans, K. Peerlinck, J.G. Gilles, J. Vermynen, J.M. Saint-Remy, Mechanisms and kinetics of FVIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor, *Blood* 92 (1998) 496–506.
- [4] E.N. van den Brink, E.A. Turenhout, J. Davies, N. Bovenschen, K. Fijnvandraat, W.H. Ouweland, M. Peters, J. Voorberg, Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes, *Blood* 95 (2000) 558–563.
- [5] K. Rajewsky, Clonal selection and learning in the antibody system, *Nature* 381 (1996) 751–758.
- [6] G.L. Bray, B.L. Kroner, S. Arkin, L.W. Aledort, M.W. Hilgartner, M.E. Eyster, M.V. Ragni, J.J. Goedert, Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the multi-center hemophilia cohort study, *Am. J. Hematol.* 42 (1993) 375–379.
- [7] S.T. Singer, J.E. Addiego, D.C. Reason, A.H. Lucas, T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors, *Thromb. Haemost.* 76 (1996) 17–22.
- [8] M.T. Reding, H. Wu, M. Krampf, D.K. Okita, B.M. Diethelm-Okita, B.A. Christie, N.S. Key, B.M. Conti-Fine, Sensitization of CD4⁺ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects, *Thromb. Haemost.* 84 (2000) 643–652.

- [9] M.T. Reding, D.K. Okita, B.M. Diethelm-Okita, T.A. Anderson, B.M. Conti-Fine, Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII, *Thromb. Haemost.* 1 (2003) 1777–1784.
- [10] M.T. Reding, D.K. Okita, B.M. Diethelm-Okita, T.A. Anderson, B.M. Conti-Fine, Epitope repertoire of human CD4(+) T cells on the A3 domain of coagulation factor VIII, *J. Thromb. Haemost.* 2 (2004) 1385–1394.
- [11] T.D. Jones, W.J. Phillips, B.J. Smith, C.A. Bamford, P.D. Nayee, T.P. Baglin, J.S. Gaston, M.P. Baker, Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII, *J. Thromb. Haemost.* 3 (2005) 991–1000.
- [12] M.T. Reding, S. Lei, H. Lei, D. Green, J. Gill, B.M. Conti-Fine, Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients, *Thromb. Haemost.* 88 (2002) 568–575.
- [13] R.A. Ettinger, E.A. James, W.W. Kwok, A.R. Thompson, K.P. Pratt, Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses, *Blood* 114 (2009) 1423–1428.
- [14] M. Algiman, G. Dietrich, U.E. Nydegger, D. Boieldieu, Y. Sultan, M.D. Kazatchkine, Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals, *Proc. Natl. Acad. Sci. USA* 89 (1992) 3795–3799.
- [15] J.G. Gilles, J.M. Saint-Remy, Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies, *J. Clin. Invest.* 94 (1994) 1496–1505.
- [16] M. Jacquemin, K. Peerlinck, Factor VIII inhibitor: affinity is the clue, *Blood* 125 (2015) 1056–1058.
- [17] C.J. Hofbauer, S.F. Whelan, M. Hirschler, P. Allacher, F.M. Horling, J.P. Lawo, J. Oldenburg, A. Tiede, C. Male, J. Windyga, A. Greinacher, P.N. Knöbl, G. Schrenk, J. Koehn, F. Scheiflinger, B.M. Reipert, Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans, *Blood* 125 (2015) 1180–1188.
- [18] J.M. Lusher, S. Arkin, C.F. Abildgaard, R.S. Schwartz, Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate previously untreated patient study group, *N. Engl. J. Med.* 328 (1993) 453–459.
- [19] C.R. Hay, C.A. Ludlam, B.T. Colvin, F.G. Hill, F.E. Preston, N. Wasseem, R. Bagnall, I.R. Peake, E. Berntorp, E.P. Mauser Bunschoten, K. Fijnvandraat, C.K. Kasper, G. White, E. Santagostino, Factor VIII inhibitors in mild and moderate-severity haemophilia A, *Thromb. Haemost.* 79 (1998) 762–766.
- [20] E. Santagostino, A. Gringeri, L. Tagliavacca, P. Mannucci, Inhibitors to factor VIII in a family with mild hemophilia: molecular characterization and response to factor VIII and desmopressin, *Thromb. Haemost.* 74 (1995) 619–621.
- [21] K. Fijnvandraat, E.A.M. Turenhout, E.N. van den Brink, J.W. ten Cate, J.A. van Mourik, M. Peters, J. Voorberg, The missense mutation Arg593 Cys is related to antibody formation in a patient with mild hemophilia A, *Blood* 89 (1997) 4371–4377.
- [22] K. Peerlinck, M. Jacquemin, M.F. Hoylaerts, J.G. Gilles, R. Lavend'homme, K.M. Johnson, K. Freson, D. Scandella, J.M. Saint-Remy, J. Vermynen, Anti-factor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A, *Blood* 93 (1999) 2267–2273.
- [23] J.G. Gilles, R. Lavend'homme, K. Peerlinck, M.G. Jacquemin, M. Hoylaerts, S. Jorieu, C. Mazurier, J. Vermynen, J.M. Saint-Remy, Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes, *Thromb. Haemost.* 82 (1999) 40–45.
- [24] M. Jacquemin, V. Vantomme, C. Buhot, R. Lavend'homme, W. Burny, N. Demotte, P. Chaux, K. Peerlinck, J. Vermynen, B. Maillere, P. van der Bruggen, J.M. Saint-Remy, CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A, *Blood* 101 (2003) 1351–1358.
- [25] E.A. James, W.W. Kwok, R.A. Ettinger, A.R. Thompson, K.P. Pratt, T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide, *J. Thromb. Haemost.* (2007) 2399–2407.
- [26] R.A. Ettinger, E.A. James, W.W. Kwok, A.R. Thompson, K.P. Pratt, HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P, *Haemophilia* 16 (2010) 44–55.
- [27] E.A. James, S.D. van Haren, R.A. Ettinger, K. Fijnvandraat, J.A. Liberman, W.W. Kwok, J. Voorberg, K.P. Pratt, T-cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site, *J. Thromb. Haemost.* 9 (2011) 689–699.
- [28] K.R. Viel, A. Ameri, T.C. Abshire, R.V. Iyer, R.G. Watts, C. Lutchter, C. Channell, S. A. Cole, K.M. Fernstrom, S. Nakaya, C.K. Kasper, A.R. Thompson, L. Almasy, T.E. Howard, Inhibitors of factor VIII in black patients with hemophilia, *N. Engl. J. Med.* 360 (2009) 1618–1627.
- [29] L.M. Aledort, D.M. Dimichele, Inhibitors occur more frequently in African-American and Latino haemophiliacs, *Haemophilia* 4 (1998) 68.
- [30] M.V. Ragni, O. Ojeifo, J. Feng, J. Yan, K.A. Hill, S.S. Sommer, M.N. Trucco, D.J. Brambilla, Hemophilia inhibitor S: risk factors for inhibitor formation in haemophilia: a prevalent case-control study, *Haemophilia* 15 (2009) 1074–1082.
- [31] G.S. Pandey, C. Yanover, L.M. Miller-Jenkins, S. Garfield, S.A. Cole, J.E. Curran, E. K. Moses, N. Rydz, V. Simhadri, C. Kimchi-Sarfaty, D. Lillicrap, K.R. Viel, T.M. Przytycka, G.F. Pierce, T.E. Howard, Z.E. Sauna, PATH (Personalized Alternative Therapies for Hemophilia) Study Investigators, Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A, *Nat. Med.* 19 (2013) 1318–1324.
- [32] C.H. Miller, J. Benson, D. Ellingsen, J. Driggers, A. Payne, F.M. Kelly, J.M. Soucie, W. Craig Hooper, Hemophilia inhibitor research study I: F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity, *Haemophilia* 18 (2012) 375–382.
- [33] J. Schwarz, J. Astermark, E.D. Menius, M. Carrington, S.M. Donfield, E.D. Gomperts, G.W. Nelson, J. Oldenburg, A. Pavlova, A.D. Shapiro, C.A. Winkler, E. Berntorp, Hemophilia inhibitor genetics study combined cohort. F8 haplotype and inhibitor risk: results from the hemophilia inhibitor genetics study (HIGS) combined cohort, *Haemophilia* 19 (2013) 113–118.
- [34] D. Gunasekera, R.A. Ettinger, S. Nakaya Fletcher, E.A. James, M. Liu, J.C. Barrett, J. Withycombe, D.C. Matthews, M.S. Epstein, R.J. Hughes, K.P. Pratt, Factor VIII gene variants and inhibitor risk in African American hemophilia A patients, *Blood* (2015) (Epub ahead of print).
- [35] H.H. Brackmann, J. Gormsen, Massive FVIII infusion in haemophiliac with factor VIII inhibitor, high responder, *Lancet* 2 (1977) 933.
- [36] S. Webb, C. Morris, C.J. Sprent, Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity, *Cell* 63 (1990) 1249–1256.
- [37] B. Rocha, H. von Boehmer, Peripheral selection of the T cell repertoire, *Science* 251 (1991) 1225–1228.
- [38] B. Pautard, R. D'Oiron, V. Li Thiao Te, R. Lavend'homme, J.M. Saint-Remy, K. Peerlinck, M. Jacquemin, Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII-specific T cells, *J. Thromb. Haemost.* 9 (2011) 1163–1170.
- [39] Y.C. Kim, A.H. Zhang, Y. Su, S.A. Rieder, R.J. Rossi, R.A. Ettinger, K.P. Pratt, E.M. Shevach, D.W. Scott, Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses, *Blood* 125 (2015) 1107–1115.